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Abstract Hepatitis C virus (HCV) infection is one of the
leading causes of hepatocellular carcinoma (HCC) world-
wide but the mechanistic basis as to how chronic HCV
infection furthers the HCC process remains only poorly
understood. Accumulating evidence indicates that HCV
core and nonstructural proteins provoke activation of the
Wnt/b-catenin signaling pathway, and the evidence sup-
porting a role of Wnt/b-catenin signaling in the onset and
progression of HCC is compelling. Convincing molecular
explanations as to how expression of viral effectors trans-
lates into increased activity of the Wnt/b-catenin signaling
machinery are still largely lacking, hampering the design of
rational strategies aimed at preventing HCC. Furthermore,
how such increased signaling is especially associated with
HCC oncogenesis in the context of HCV infection remains
obscure as well. Here we review the body of contemporary
biomedical knowledge on the role of the Wnt/b-catenin
pathway in the progression from chronic hepatitis C to
cirrhosis and HCC and explore potential hypotheses as to
the mechanisms involved.
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Abbreviations
APC Adenomatous polyposis coli
EGFR Epidermal growth factor receptor
ERK Extracellular-signal-regulated kinase
FGF Fibroblast growth factor
FZD Frizzled
GSK3b Glycogen synthase kinase 3b
HBV Hepatitis B virus
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
LECT2 Leukocyte-cell-derived chemotaxin 2
MEK Mitogen-activated protein kinase kinase
MMP Matrix metalloproteinase
PI3K Phosphoinositide 3-kinase
RNF43 Ring finger protein 43
SHP-2 Src homology region 2 domain containing
phosphatase 2
ZNRF3 Zinc/ring finger protein 3
Introduction
Hepatitis C virus (HCV) is estimated to infect up to 2% of
the global population (around 180 million people world-
wide) [1], with approximately 3 million to 4 million new
infections each year [2, 3]. Following infection, 60–80% of
affected individuals eventually develop chronic hepatitis
[4]. After around 10 years of infection, 5–10% of these
chronically infected patients develop cirrhosis [5]. In
addition to the high mortality associated with advanced
cirrhosis per se, annually another 2.0–6.6% of cirrhotic
patients with HCV infection develop hepatocellular carci-
noma (HCC) [6, 7]. Understanding the details as to how
HCV infection can promote the HCC process is thus of
critical importance for the rational design of novel avenues
aimed at the prevention and treatment of HCC.
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Distinct from hepatitis B virus (HBV), a DNA virus that
can integrate into the human genome and thus directly
provoke genomic alterations potentially leading to cancer
[8], HCV is a RNA virus lacking a DNA intermediate
phase in its life cycle, and therefore its infection of liver
cells is not associated with damage to the host genetic
material per se [9]. Hence the tumor-promoting potential of
HCV derives from indirect interaction with the hepatocyte
genome. It thus appears that HCV has specific properties
that promote further hepatocyte transformation.
The Wnt/b-catenin pathway is an attractive candidate to
mediate the HCV-specific effects leading to hepatocyte
oncogenic transformation. Activation of this pathway
clearly contributes to hepatocarcinogenesis as indicated by
the detection of recurrent genetic mutations of Wnt/b-
catenin signaling pathway components in HCC that appear
especially frequent in HCV-related tumors. HCV-derived
viral proteins appear to be capable of autonomous activa-
tion of Wnt/b-catenin signaling, although the underlying
molecular mechanisms remain poorly understood. Here we
explore potential hypotheses explaining these effects and
summarize documented interactions of Wnt/b-catenin sig-
naling components in HCC patients with HCV infection.
We propose that the Wnt/b-catenin signaling pathway
constitutes a rational target for the prevention and treat-
ment of HCV-associated HCC.
Wnt/b-catenin signaling
Wnt/b-catenin signaling is a pivotal morphogenetic path-
way and accordingly is associated with a host of physio-
logical and pathophysiological processes, including
embryonic patterning, cell proliferation, cell differentia-
tion, angiogenesis, and especially cancer [10–12]. Wnt
signaling is initiated by binding of Wnt ligands to their
cognate receptors. These Wnt ligands are 40-kDa cysteine-
rich glycoproteins [13], which following synthesis and
primary glycosylation on the endoplasmic reticulum are
palmitoylated by Wnt acyltransferase porcupine protein in
the Golgi apparatus. Secretion of Wnts then requires
evenness interrupted/Wntless/G-protein-coupled receptor
177, which shuttles palmitoylated Wnts to the plasma
membrane, where they are released by the cell and initiate
autocrine or paracrine signaling. Hitherto, 19 Wnts have
been identified in the human genome [14], and because
annotation of Homo sapiens DNA is now quite complete, it
is unlikely further Wnt paralogues will be discovered. Wnts
can provoke different modes of cellular signaling, either
mediated by b-catenin or independent of this protein.
According to the dependence on b-catenin for provoking
cellular effects, Wnts are classified into canonical (b-
catenin-dependent) and noncanonical (b-catenin-
independent) subgroups [15, 16]. In this review we will
focus on the canonical Wnts, as these are most associated
with HCC in general and HCV-infection-associated HCC
in particular.
Except for several stem cell niches, canonical Wnt/b-
catenin signaling is typically not active in tissues of adult
individuals [17], despite constitutive production of Wnt
ligands. This is a result of the action of a range of Wnt
antagonists, such as secreted frizzled (FZD)-related pro-
teins, dickkopf, and Wnt inhibitory factor [18]. In this
nonsignaling state, cytosolic b-catenin is continuously
phosphorylated at Ser33, Ser37, Thr41, and Ser45 residues
located in exon 3 by a multiprotein complex consisting of
adenomatous polyposis coli (APC), axin, glycogen syn-
thase kinase 3b (GSK3b), and casein kinase 1. These
phosphorylations cause b-catenin to be recognized and
polyubiquitinated by b-transducin repeat containing pro-
tein, followed by b-catenin degradation in the proteasome
[18, 19]. The overall effect is that minimal free cytosolic b-
catenin is available for nuclear signaling, and thus Wnt-
mediated gene transcription is absent under normal
conditions.
On binding of Wnt ligands to a complex consisting of
the FZD receptor and coreceptors, which include low-
density lipoprotein receptor related protein 5/6, the scaf-
folding protein disheveled is recruited to the membrane, an
event that in turn causes the disassembly of the multipro-
tein b-catenin destruction complex. This results in rescue
of b-catenin from proteasomal degradation and thus the
accumulation of b-catenin in the cytoplasm, eventually
causing b-catenin translocation to the nucleus [20]. In the
nucleus, b-catenin binds transcription factors of the T-cell
factor 4 (transcription factor 7, transcription factor 7
like 1, and transcription factor 7 like 2)/lymphoid enhan-
cer binding factor family, triggering transcription of
downstream Wnt target genes, including CYCLIND1,
AXIN2, MYC, RNF43 (which encodes ring finger pro-
tein 43, RNF43), and ZNRF3 (which encodes zinc/ring
finger protein 3, ZNRF3) [21, 22]. RNF43 and ZNRF3 are
two closely related transmembrane E3 ligases, which
remove surface FZD receptors by promoting their endo-
cytosis [23]. This E3 ligase activity is in turn negatively
modulated by R-spondins and leucine-rich repeat contain-
ing G-protein-coupled receptor 4/5/6, which sequestrate
RNF43 and ZNRF3 from FZD receptors by forming a tri-
partite complex [24]. Hence regulation of Wnt target gene
transcription is complex, allowing extensive regulation but
also mechanisms leading to deregulation of target gene
transcription in pathophysiology.
Further complexity is added by the role of b-catenin in
cell–cell adhesion, where it acts, independent of its tran-
scriptional activity, by forming a complex with cadherins
and facilitating the formation of cellular junctions between
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adjacent hepatocytes. The b-catenin captured in these cell-
adhesion complexes represents a dynamic pool of b-cate-
nin capable of nuclear signaling following several stimuli.
One of these stimuli is b-catenin tyrosine phosphorylation
by receptor tyrosine kinases activated by growth factors
produced by epithelial and stromal cells. In particular,
phosphorylation of the b-catenin residue Tyr654 results in
its release from cadherins and an increase in T-cell-factor-
mediated transcriptional activity [25–28]. Furthermore, the
adherence pool of b-catenin also appears to be under
indirect control of Wnt signaling itself. On activation of
canonical Wnt/b-catenin signaling, the suppression of
GSK3b leads to the upregulation of SNAIL [29]. As
SNAIL is a repressor of the CDH1 gene encoding E-cad-
herin [30, 31], this will lead to reduced E-cadherin pro-
duction. Diminished E-cadherin production causes the
dissociation of the complex and subsequent internalization
of b-catenin and accumulation of b-catenin in the perinu-
clear endocytic recycling compartment, which promotes
translocation to the nucleus to activate Wnt/b-catenin sig-
naling [32, 33]. Hence pathogens can also provoke b-
catenin signaling by disrupting intercellular junctions, in
addition to direct effects on elements of the Wnt signaling
cascade involved in regulating b-catenin-mediated
transcription.
Aberrant activation of Wnt/b-catenin signaling
during HCC
Important in the context of potential modulation by HCV
infection in relation to HCC is that aberrant signal trans-
duction in general and b-catenin signaling in particular is
one of the key characteristics of hepatocarcinogenesis [34].
Functional deregulation of Wnt/b-catenin signaling is
reported frequently in HCC, strongly suggesting that this
pathway is important in this tumor type. Various genetic
and molecular alterations have been identified to be pro-
oncogenic in a variety of settings, and have as a common
denominator that they stabilize b-catenin, thus provoking
enhanced transcriptional activity of Wnt target genes.
Table 1 summarizes the relative mutation frequency of
Wnt/b-catenin signaling elements in HCC patients. From
HCC cohorts from different countries, the most prevalent
are activating mutations in CTNNB1 (which encodes b-
catenin), followed by loss-of-function mutations in AXIN1,
AXIN2, and APC. The relative mutation frequencies of
these various Wnt/b-catenin signaling elements are differ-
ent in HCC as compared with other cancers (e.g., sporadic
colorectal cancer). The reason that these differences
emerge may result from different causes of HCC and thus
the type of mutations induced in liver genomes as com-
pared with other sites in the body, but may also derive from
the fact that in different organs, optimal cancer-driving
Wnt/b-catenin signaling mutations may be substantially
different, resulting in selection pressure for different types
of mutations [35, 36]. As indicated in Table 1, around
22.1% of HCCs harbor specific gain-of-function mutations
of CTNNB1. Missense, insertion, or partial deletions within
CTNNB1 exon 3 lead to the generation of a mutant b-
catenin preventing the proper phosphorylation of amino
acids Ser33, Ser37, Thr41, and Ser45, resulting in com-
promised degradation and thus stabilization of b-catenin in
the cytoplasm. Less frequently, loss-of-function mutation
of AXIN1, AXIN2, or APC is found in 3.2%, 0.4%, and
0.2% of HCCs respectively, evidently contrasting with the
situation in colorectal cancer, where up to 80% of cancers
display mutated APC [36, 37]. Frameshift in or deletion of
these genes yields impaired ability of the destruction
complex to degrade b-catenin and is thus also associated
with enhanced Wnt/b-catenin signaling. Overexpression of
upstream ligands or cell surface receptors and reduction of
expression of extracellular inhibitors have been reported to
stimulate activation of this pathway in HCC as well [38].
Thus at some stage in the progression toward full-blown
HCC, acquisition of increased Wnt/b-catenin signaling
provides liver cancer cells with a relative advantage over
cells not having such mutations. Here we will argue that
especially HCV infections create the conditions that allow
precarcinogenic cancer cells to exhibit such enhanced Wnt/
b-catenin signaling.
High frequency of CTNNB1 mutation in HCV-
related HCC
HCV infection presents a substantial clinical challenge,
for which only direct antiviral medication appears to be a
suitable solution [75]. If left untreated or not recognized
soon enough, persistent HCV infection causes immune-
mediated chronic liver damage and compensatory hepatic
regeneration by inducing cell proliferation and thus cre-
ates a microenvironment permissive for the induction of
genetic alterations to the hepatocyte genome [76]. Fol-
lowing HCV infections, genetic abnormalities accumulate
relatively slowly during the sequence of chronic hepatitis
and increased cirrhosis that finally progresses to HCC.
Consequently, the selective growth advantage provided to
hepatocytes with a malignant phenotype eventually facil-
itates the development of phenotypically and genetically
heterogeneous HCC [77]. The relatively high frequency of
mutations of CTNNB1 (one of the principal proto-onco-
genes in HCC development) in HCV-related HCC is
especially striking, in the view of the relative absence of
such mutations in HBV-related liver cancers but also in
the view of their paucity in non-virally-associated HCC
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(Table 2). Around 26.7% of HCV-related HCCs harbor a
CTNNB1 mutation, which is a much higher frequency
than that observed in HBV-associated HCC (11.6%) or
that observed in total non-virally-associated HCC
(21.2%). Furthermore, we noticed that, differently from
colorectal cancers, which mainly show Thr41 and Ser45
mutations [36], HCV-related HCC shows a preference for
CTNNB1 mutations from Asp32 to Ser37 residues
[45, 47, 49, 59, 68, 70, 71] (Fig. 1). Recently, a genotype–
phenotype correlation was shown for CTNNB1 mutations,
suggesting that activating mutations occurring at the
Asp32 to Ser37 residues lead to higher signaling levels
Table 1 Genetic mutation in components of the Wnt/b-catenin pathway in hepatocellular carcinoma
References Patients Mutant samples Region
CTNNB1 AXIN1 AXIN2 APC
Rebouissou et al. [39] 373 146 (39%) NA NA NA France, Spain, Italy
Hirotsu et al. [40] 9 2 (22.2%) NA NA NA Japan
Schulze et al. [41] 243 95 (37.4%) 27 (11.1%) 3 (1.2%) 4 (1.6%) France, Italy, Spain
Kan et al. [42] 88 14 (15.9%) 4 (4.5%) 2 (2.3%) 2 (2.3%) China
Kitao et al. [43] 134 27 (20.1%) NA NA NA Japan
Ding et al. [44] 156 15 (9.6%) NA NA NA China
Tornesello et al. [45] 67 10 (14.9%) NA NA NA Southern Italy
Cleary et al. [46] 87 20 (22.9%) NA NA NA Canada, USA
Guichard et al. [47] 125 41 (32.8%) 19 (15.2%) NA 2 (1.6%) France
Lachenmayer et al. [48] 90 29 (32.2%) NA NA NA USA, Netherlands, Italy, Spain, Germany
Li et al. [49] 139 28 (20.1%) NA NA NA USA, Netherlands, China
Cieply et al. [50] 32 9 (28.1%) NA NA NA USA
Bengochea et al. [38] 62 16 (25.8%) NA NA NA Thailand, France
Austinat et al. [51] 40 10 (25%) 2 (5%) NA NA Germany
Kim et al. [52] 36 1 (2.8%) 9 (25%) NA NA Korea
Zucman-Rossi et al. [53] 45 18 (40%) 5 (11.1%) NA NA France
Boyault et al. [54] 120 34 (28.3%) 13 (10.8%) NA NA France
Zucman-Rossi et al. [55] 96 12 (12.5%) NA NA NA France
Park et al. [56] 81 13 (16%) 5 (6.2%) NA NA Korea
Ishizaki et al. [57] 89 10 (11.2%) 13 (14.6) 9 (10.1%) NA Japan
Cui et al. [58] 34 15 (44.1%) NA NA NA China
Edamoto et al. [59] 100 24 (24%) NA NA 0 Japan, Switzerland
Taniguchi et al. [60] 73 14 (19.2%) 7 (9.6%) 2 (2.7%) NA UK
Wong et al. [61] 60 7 (11.7%) NA NA NA China
Mao et al. [62] 262 37 (14.1%) NA NA NA Taiwan
Cui et al. [63] 34 15 (44.1%) NA NA NA China
Laurent–Puig et al. [64] 137 26 (19%) 12 (8.8%) NA NA France
Devereux et al. [65] 62 5 (8.1%) NA NA NA China
Hsu et al. [66] 434 57 (13.1%) NA NA NA Taiwan
Satoh et al. [67] 87 0 (0%) 5 (5.7%) NA NA Japan
Huang et al. [68] 22 9 (41%) NA NA NA Japan, Switzerland
Legoix et al. [69] 119 21 (17.6%) NA NA NA France
Terris et al. [70] 73 14 (19.2%) NA NA NA France
Kondo et al. [71] 38 9 (24%) NA NA NA Japan
Van Nhieu et al. [72] 35 12 (34.3%) NA NA NA France
Miyoshi et al. [73] 75 14 (18.7%) NA NA NA Japan
de La Coste et al. [74] 31 8 (25.8%) NA NA NA France
Total 3788 837 (22.1%) 121 (3.2%) 16 (0.4%) 8 (0.2%)
NA not analyzed
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than mutations at Thr41 and Ser45 [39]. This may par-
tially explain the preference. It also could be
attributable to the mutagenic dose required to induce
HCC. Mutations at Ser45 require the selective duplication
of the mutated allele as a second activating hit, whereas
only one activating hit is required for mutations at Asp32
to Ser37.
Although CTNNB1 mutation appears to be a late-stage
event in the progression to HCC [56], the high rate of
CTNNB1 mutations observed may be directly and causally
related to the HCV infectious process as in vitro studies
show that both acute and chronic HCV infections provoke
specifically CTNNB1 mutations in hematological model
systems and HCCs [78]. Evidently, clarification of the
relationship between infection with a nonintegrating virus
and subsequent CTNNB1 mutations may prove exceedingly
useful for the design of strategies aimed at preventing
HCV-associated HCC.
Table 2 Comparison of CTNNB1 mutation in subtypes of hepatocellular carcinoma
References CTNNB1 mutant samples Mutation
type
Amino acid Region
HCV HBV NV
Hirotsu et al.
[40]
2/5 (40%) 0/1 (0%) 0/3 (0%) Missense Gly34, His36 Japan
Kitao et al. [43] 12/55
(21.8%)
4/34
(11.8%)
11/44
(25%)
NA NA Japan
Ding et al. [44] NA 12/110
(10.9%)
3/46 (6.5%) Missense Asp32, Gly34, Ser37, Thr41, Ser45 China
Tornesello et al.
[45]
10/57
(17.5%)
0/10 (0%) NA Missense Asp32, Ser33, Gly34 Ile35, Ser37, Ser45 Southern Italy
Kan et al. [42] NA 12/81
(14.8%)
NA Missense Asp32, Ser33, Gly34 Ile35, Ser37, Thr41,
Ser45
China
Guichard et al.
[47]
8/24
(33.3%)
4/35
(11.4%)
30/80
(37.5%)
Missense
Insertion
Deletion
Asp32, Ser33, Ser37, Thr41,Thr42, Ser45 France
Li et al. [49] 14/45
(31.1%)
6/52
(11.5%)
9/44
(20.5%)
Missense
Deletion
Asp32, Ser33, Gly34, His36, Ser37, Thr41,
Ser45, Asn387
USA, Netherlands,
China
Bengochea et al.
[38]
8/20 (40%) 3/18
(16.7%)
5/24
(20.8%)
Missense
Insertion
Asp32, Ser33, Ser37, Thr41 Ser45 Thailand, France
Kim et al. [52] 0/4 (0%) 0/21 (0%) 1/14 (7.1%) Missense Ser33 China
Park et al. [56] 0/6 (0%) 13/78
(16.7%)
NA Missense
Deletion
Asp32, Ser33, Gly34 Ile35, His36, Ser37,
Thr41, Ser45
Korea
Edamoto et al.
[59]
16/51
(31.4%)
5/26
(19.2%)
3/23 (13%) Missense Asp32, Ser33, His36, Ser37, Thr41, Ser45 Japan, Switzerland
Wong et al. [61] 0/2 (0%) 5/48
(10.4%)
2/10 (20%) Missense
Deletion
Asp32, Ser33, Gly34 Ile35, Ser37, Thr41,
Ser45
China
Hsu et al. [66] 23/92 (25%) 30/323
(9.3%)
4/19
(21.1%)
Missense
Deletion
Asp32, Gly34,
Thr41, Ser45
Taiwan
Huang et al.
[68]
9/22 (41%) NA NA Missense Asp32, Ser33, Ser37,
Thr41, Ser45
Japan, Switzerland
Legoix et al.
[69]
7/30
(23.3%)
5/26
(19.2%)
13/64
(20.3%)
Missense
Deletion
Asp32, Ser33, Gly34, Ser37, Thr41, Ser45 France
Terris et al. [70] 2/7 (28.6) 3/14 (21.4) 9/52 (17.3) Missense
Deletion
Asp32, Ser33, Gly34, Ser37, Ser45 France
Kondo et al.
[71]
7/22
(31.8%)
1/8 (12.5%) 1/9 (11.1%) Missense
Deletion
Asp32, Ser33, Gly34, Ile35, His36, Ser37,
Thr41, Ser45
Japan
Total 118/442
(26.7%)
103/885
(11.6%)
91/432
(21.1%)
HBV hepatitis B virus, HCV hepatitis C virus, NA not analyzed, NV not viral
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HCV structural proteins activate Wnt/b-catenin
signaling
The HCV genome is a single-stranded positive-sense 9.6-
kb RNA molecule, which includes a single open reading
frame encoding a polyprotein of approximately 3000
amino acids that following translation is cleaved into ten
mature proteins by both host and viral proteases. These
proteins are the structural proteins (core, E1 and E2),
viroporin p7, and the nonstructural proteins (NS2, NS3,
NS4A, NS4B, NS5A, and NS5B). The pro-oncogenic
pathogenesis of HCV appears mainly mediated by the core
protein and two of the nonstructural proteins, NS3 and
NS5A [79]. These pro-oncogenic effects appear to depend
largely on the potential of these proteins to mediate acti-
vation of Wnt/b-catenin signaling.
Core protein
The 21-kDa core protein is the major component of HCV.
Despite lacking obvious organelle localization signals in
the primary sequence, it is detected not only in the cytosol
but also in the Golgi apparatus, in lipid droplets, and in the
nucleus [80, 81]. Remarkably, in the latter organelle it
serves as a regulator of hepatocyte transcription, facilitat-
ing Wnt/b-catenin signaling. This is brought about by
upregulation of canonical Wnts, FZD receptor, and low-
density lipoprotein receptor related protein 5/6 [82, 83]
while concomitantly inhibiting transcription of the Wnt
antagonists secreted FZD-related protein 2 and dickkopf 1
[84]. The latter effect is mediated by epigenetic silencing
of the promoters involved in core-protein-mediated
recruitment of DNA methyltransferase 1 and histone
deacetylase 1 to the transcription start site, an effect
already detected early in hepatitis infection [84, 85]. In
addition, the HCV core protein mediates hypermethylation
of the CDH1 (E-cadherin) gene promoter [86]. Reduced
production of E-cadherin results in diminished sequestering
of b-catenin in b-catenin–E-caherin complexes and thus
enhanced activation of Wnt/b-catenin signaling (Fig. 2).
Hence the core protein mediates a plethora of molecular
events leading to increased Wnt/b-catenin signaling and
thus apparently HCV is under substantial selection pressure
to provoke Wnt/b-catenin signaling. Potential sources for
this selection pressure are a necessity to counteract hepa-
tocyte apoptosis, whereas Wnt/b-catenin signaling driven
expansion of the HCV-infected compartment may be
involved as well.
NS5A
The notion that HCV is under selection pressure to coun-
teract apoptosis is further reinforced by observations that
NS5A not only functions as a component of the HCV RNA
replication complex [87] but also binds to the p85 regula-
tory subunit of phosphoinositide 3-kinase (PI3K), thus
activating the downstream effector serine/threonine kinase
Akt [88, 89]. Akt activation provides a powerful
Fig. 1 Summary of CTNNB1
exon 3 mutations in hepatitis C
virus related hepatocellular
carcinoma. The locations of the
CTNNB1 mutations reported in
68 tumors from 65
hepatocellular carcinoma
patients (one tumor with
p.D32_G48del, not shown) are
illustrated. N-terminal serine
and threonine phosphorylation
residues are indicated in bold.
Numbers in parentheses are the
absolute number of tumors
tested with the given mutation
J Gastroenterol
123
antiapoptotic signal and also mediates the inactivation of
GSK3b, stabilization of b-catenin, and subsequent stimu-
lation of b-catenin-dependent transcription [90]. In addi-
tion, the NS5A protein binds and stabilizes b-catenin
directly [91], apparently independent of its effects on Akt
and GSK3b [92] (Fig. 2). Thus the multiple stimulatory
effects of NS5A on Wnt/b-catenin signaling are also tes-
timony to the selection pressure of HCV to increase hep-
atocyte Wnt/b-catenin signaling.
More Wnt/b-catenin signaling stimulating effects
The hypotheses that successful HCV infection critically
depends on its potential to stimulate Wnt/b-catenin sig-
naling is further supported by observations that, in addition
to direct activation, HCV infection leads to elevation of the
levels of miR-155 [93] and miR-199a-5p [94], in turn
triggering Wnt/b-catenin signaling. MicroRNA miR-155
acts as an oncomiR by targeting the suppressor of the
suppressor of cytokine signaling 1 gene (SOCS1) [95],
which directly inhibits APC expression, one of the major
negative regulators of Wnt/b-catenin signaling [93].
Moreover, both direct and indirect activation by HCV viral
proteins may explain the notable dysregulation of Wnt/b-
catenin signaling in hepatitis C and the related HCC sub-
class. Moreover, HCV core, NS3, and NS5A proteins may
facilitate further oncogenic transformation of infected
hepatocytes [79] by suppression of DNA repair mecha-
nisms, potentially causing CTNNB1 mutations. Support for
this idea can be found in the observation that in experi-
mental animals the hepatocarcinogenic nitrosamine
diethylnitrosamine provokes cancer by inducing CTNNB1
mutations [96, 97], and thus increased mutagenic pressure
through corruption of DNA repair may be preferentially
associated with this mutation. Hence the effects on the
DNA repair machinery exerted by HCV core, NS3, and
NS5A may link increased Wnt/b-catenin signaling medi-
ated by direct effects of these proteins early in infection to
mutation-mediated activation of Wnt/b-catenin signaling
later in the progression to HCC.
Fig. 2 Wnt/b-catenin signaling is activated by hepatitis C virus
(HCV) proteins. HCV core protein elevates gene expression of Wnt
ligands, frizzled (FZD) receptor, and low-density lipoprotein receptor
related protein 5/6 (LRP5/6) but decreases the expression of the Wnt
antagonists dickkopf (DKK) and secreted frizzled-related protein
(SFRP) by recruiting DNA methyltransferase 1 (DNMT1) and histone
deacetylase 1 (HDAC1) to their transcription start sites. In addition,
HCV core protein releases b-catenin from the b-catenin–E-cadherin
complexes by suppression of the CDH1 gene promoter (which
encodes E-cadherin). NS5A protein activates phosphoinositide 3-ki-
nase (PI3K)/Akt signaling, leading to the inactivation of glycogen
synthase kinase 3b (GSK3b) and subsequent reduced breakdown of b-
catenin, or directly stabilizes b-catenin. The overall effect is the
cytoplasmic accumulation of b-catenin and stimulation of down-
stream transcription
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Wnt/b-catenin signaling paves the way
for progression of chronic hepatitis C to HCC
Inflammation
The HCV battles with the immune system. Thus negative
modulation of inflammatory responses through enhanced
Wnt/b-catenin signaling could conceivably provide further
selection pressure for HCV to acquire Wnt/b-catenin sig-
naling activating properties. However, the effect of Wnt/b-
catenin signaling on hepatocyte immune responses remains
controversial. On one hand, Wnt/b-catenin signaling could
suppress the immune response by blunting T-cell activation
[98, 99], reducing release of tumor necrosis factor [100] or
stimulating the production of the chemokine-like chemo-
tactic factor leukocyte-cell-derived chemotaxin 2 (LECT2)
and invariant natural killer T cell responses, both of which
relay anti-inflammatory response [101]. On the other hand,
Wnt/b-catenin signaling triggers inflammatory responses
by activating the proinflammatory nuclear factor jB path-
way, as evident from experimentation in a hepatocyte-
specific APC and LECT2 knockout (Apc-/-Lect2-/-)
mouse model [101]. In potential agreement, germline
genetic variations in Wnt/b-catenin signaling elements
were significantly associated with the risk of inflammation
in HCV-infected male patients [102]. Thus the issue as to
how HCV-elicited Wnt/b-catenin signaling relates to HCV-
provoked inflammation warrants further experimentation.
Fibrosis to cirrhosis and HCC development
Chronic inflammation evoked by HCV infection may cul-
minate in liver fibrosis. Such fibrosis progresses gradually
and disrupts liver physical structure and function over the
course of several decades, finally resulting in fatal diseases
such as cirrhosis and HCC [103]. Given HCV-stimulation
of Wnt/b-catenin signaling probably evolved to support the
early phases of viral infection, emerging data suggest that
Wnt/b-catenin signaling activated by HCV participates in
the pathogenesis of liver fibrosis as well [102, 103], mainly
by enhancing hepatic stellate cell activation and survival
[104]. The subsequent progression toward full-blown HCC
is a complex process involving many various signaling
pathways, but especially cross talk between epidermal
growth factor receptor (EGFR) signaling and fibroblast
growth factor (FGF) receptor signaling and aberrant acti-
vation of Wnt/b-catenin signaling appears important here.
The EGFR pathway controls a variety of signals ranging
from cell proliferation, cell motility, and apoptosis
decrease to epithelial–mesenchymal transition, upregula-
tion of matrix metalloproteinases (MMPs), and even stem
cell maintenance [105]. EGFR is highly expressed in the
adult liver [106] and plays an essential role in the G1–S
phase transition for hepatocyte proliferation [107]. EGFR
pathway dysregulation has been reported in 60–80% of
HCC patients [108], and is associated with the late stages
and the degree of tumor differentiation [109, 110]. EGFR
favors HCV entry through co-internalization of an HCV–
CD81–EGFR complex following binding of EGFR ligands
to the receptor and subsequent endocytosis [111, 112].
Following clathrin-mediated endocytosis of EGFR, EGFR
is routed for eventual intracellular degradation [113]. The
viral NS5A protein, however, perturbs EGFR trafficking
and degradation, increasing EGFR signaling and con-
tributing to HCV-mediated HCC development [114].
Binding of Wnt1 and Wnt5a to FZD transactivates EGFR
signaling by MMP-mediated release of soluble EGFR
ligands, such as transforming growth factor a [115].
Activated b-catenin might form heterodimers with EGFR
to enhance EGFR pathway activation [116]. Conversely,
EGFR signaling contributes to Wnt/b-catenin signaling in
various ways. Firstly, EGFR can directly induce tyrosine
phosphorylation of b-catenin at residue Tyr654, thereby
decreasing the binding with cell-adhesion complexes and
releasing it for nuclear signaling [104, 117]. This phe-
nomenon has been observed for a large number of growth
factors signaling through receptor tyrosine kinases, such as
hepatocyte growth factor and FGFs that are produced in
excess by the cirrhotic tissue adjacent to tumor tissue
[28, 118–120]. Secondly, EGFR stimulates the PI3K/Akt
and Ras/Raf/mitogen-activated protein kinase kinase
(MEK)/extracellular-signal-regulated kinase (ERK) cas-
cades that both can promote b-catenin signaling through
inhibition of GSK3b activity [121–125] (Fig. 3). Thus
HCV-mediated activation of Wnt/b-catenin signaling may
initiate a vicious interaction between EGFR and Wnt sig-
naling, promoting potentially pro-oncogenic hepatocyte
proliferation.
Similarly to the EGFR pathway, FGF-initiated signaling
is a cardinal regulator of hepatocyte proliferation, differ-
entiation, embryonic development, and organogenesis as
well as hepatic tumorigenesis [126, 127]. Especially in
chronic hepatitis C associated HCC, activation of FGF
signaling is observed [128, 129] and increased FGF levels
are associated with enhanced HCV replication and release
of infectious particles [130]. Cross talk of Wnt and FGF
pathways in HCV-related HCC is supported by observa-
tions that FGF signaling leads to the release of b-catenin
from the b-catenin–E-cadherin complexes because of the
phosphorylation of Tyr654 as described above. Further-
more, FGF2 increases expression of b-catenin messenger
RNA, upregulates b-catenin nuclear translocation, and
inactivates GSK3b [131], probably mediated through
activation of the PI3K/Akt and Ras/Raf/MEK/ERK path-
ways. Conversely, Wnt/b-catenin signaling is able to acti-
vate FGF signaling by increasing FGF18 and FGF20
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expression [132] (Fig. 3). Thus again, vicious interaction
between Wnt/b-catenin signaling and FGF signaling
appears to occur.
It has been reported that the Src homology region 2
domain containing phosphatase 2 (SHP-2) can be activated
by HCV structural protein E2 [133]. Thus conceivably
SHP-2 may be an effector of EGFR and FGF signaling in
HCV-related HCC. Overexpression of SHP-2 promotes
liver tumor cell growth and metastasis by coordinately
activating not only the PI3K/Akt and Ras/Raf/MEK/ERK
pathways [121] but also Wnt/b-catenin signaling [134].
The latter effect is due to tyrosine dephosphorylation of
parafibromin (encoded by CDC73), acting as a tumor
suppressor inhibiting CYCLIND1 and MYC, together with
suppressor of variegation 3-9 homolog 1. As a result,
parafibromin acquires the ability to bind b-catenin stably,
overriding the repression effect and inducing the
expression of Wnt target genes [134] (Fig. 3). Together,
these results suggest that SHP-2 is one of the critical
molecules whose expression is enhanced during early HCV
infection and contributes to the later progression to final
HCC, which needs further investigation.
Conclusion
As one of the important cascades involved in HCV-related
HCC initiation and development, Wnt/b-catenin signaling
is aberrantly activated by HCV viral core and NS5A pro-
teins. In turn, stimulated Wnt/b-catenin signaling promotes
progression of hepatitis C during inflammation and fibrosis,
eventually promoting cirrhosis and HCC. This interaction
is further aggravated by a vicious circle involving the
EGFR and FGF pathways.
Fig. 3 Cross talk of the Wnt/b-catenin pathway with the epidermal
growth factor receptor (EGFR) and fibroblast growth factor (FGF)
pathways in hepatitis C virus (HCV)-related hepatocellular carci-
noma. HCV promotes Wnt signaling as well as the EGFR and FGF
pathways. The the Wnt/b-catenin and EGFR pathways activate each
other. Binding of Wnt ligands with frizzled (FZD) receptors
transactivates EGFR signaling by matrix metalloproteinase (MMP)-
mediated release of soluble EGFR ligands. EGFR signaling transac-
tivates Wnt/b-catenin signaling through the phosphoinositide 3-kinase
(PI3K)/Akt and Ras/Raf/mitogen-activated protein kinase kinase
(MEK)/extracellular-signal-regulated kinase (Erk) pathways but also
by releasing b-catenin from b-catenin–E-cadherin complexes as a
result of Tyr654 phosphorylation. Activated b-catenin forms
heterodimers with EGFR and in turn promotes the EGFR pathway.
On the other hand, Wnt signaling stimulates FGF signaling by
inducing FGF18 and FGF20 ligand expression. In turn, the associ-
ation of FGF19 with FGFR leads to the release of b-catenin from the
b-catenin–E-cadherin complexes. FGF2 signaling inhibits glycogen
synthase kinase 3b (GSK3b) activity through the PI3K/Akt and Ras/
Raf/MEK/Erk pathways. Activated Src homology region 2 domain
containing phosphatase 2 (SHP2) in the PI3K/Akt pathway and the
Ras/Raf/MEK/Erk pathway dephosphorylates parafibromin, which
acquires the ability to bind b-catenin stably, overriding the repression
effect on CYCLIND1 and MYC expression and triggering downstream
signaling
J Gastroenterol
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